Publication | Closed Access

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Phase 3BTreatment And PreventionClinical EpidemiologyAntiviral TherapyPharmacotherapyHiv-1 InfectionChronic Viral InfectionAntiviral DrugHivPublic HealthMedicineEpidemiologyLong-acting Cabotegravir